Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Accumulated Expenses: 2020-2024

Historic Other Accumulated Expenses for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $3.0 million.

  • Apellis Pharmaceuticals' Other Accumulated Expenses fell 78.22% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 78.22%. This contributed to the annual value of $3.0 million for FY2024, which is 75.56% down from last year.
  • Apellis Pharmaceuticals' Other Accumulated Expenses amounted to $3.0 million in FY2024, which was down 75.56% from $12.2 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $16.1 million for FY2020, and its period low was $3.0 million during FY2024.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $12.2 million (2023), whereas its average is $9.7 million.
  • In the last 5 years, Apellis Pharmaceuticals' Other Accumulated Expenses rose by 7.88% in 2022 and then crashed by 75.56% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $16.1 million in 2020, then declined by 20.48% to $12.8 million in 2021, then climbed by 7.88% to $13.8 million in 2022, then fell by 11.94% to $12.2 million in 2023, then plummeted by 75.56% to $3.0 million in 2024.